Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
We used positron emission tomography and [11C]flumazenil to analyze the benzodiazepine receptor binding in symptomatic and asymptomatic carriers of the Huntington's disease gene. We found an inverse relationship between [11C]flumazenil and [11C]raclopride binding in the putamen of symptomatic patients, and interpret this result as GABA receptor upregulation.
Künig
G
G
PSI, Paul Scherrer Institut, PET Program, Villigen, Switzerland.
Leenders
K L
KL
Sanchez-Pernaute
R
R
Antonini
A
A
Vontobel
P
P
Verhagen
A
A
Günther
I
I
D000328:Adult; D002250:Carbon Radioisotopes; D002421:Caudate Nucleus / Q000000981:diagnostic imaging / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000493:pharmacokinetics; D005260:Female; D005442:Flumazenil / Q000493:pharmacokinetics*; D018757:GABA Modulators / Q000493:pharmacokinetics*; D006801:Humans; D006816:Huntington Disease / Q000000981:diagnostic imaging* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011699:Putamen / Q000000981:diagnostic imaging / Q000378:metabolism*; D020891:Raclopride / Q000493:pharmacokinetics; D011963:Receptors, GABA-A / Q000378:metabolism*; D014055:Tomography, Emission-Computed
D002250:Carbon Radioisotopes; D018492:Dopamine Antagonists; D018757:GABA Modulators; D011963:Receptors, GABA-A; D005442:Flumazenil; D020891:Raclopride